MDSC percentage and the expressions of RORα mRNA，IL-17E mRNA and FOXP3 mRNA in rectal cancer patients

doi:10.3969/j.issn.1673-8640.2023.01.005

Abstract

Abstract:

Objective To investigate the retinoid-related orphan receptor alpha（RORα） mRNA，interleukin-17E（IL-17E） mRNA and forkhead box protein P3（FOXP3） mRNA in peripheral blood mononuclear cells（PBMC） and myelogenous suppressor cell（MDSC） percentage of patients with rectal cancer. Methods The clinical data of 95 patients with rectal cancer（rectal cancer group） and 45 healthy subjects（healthy control group） were collected，and the expressions of RORα mRNA，FOXP3 mRNA and IL-17E mRNA in PBMC and MDSC percentage were determined. Results The relative expression levels of FOXP3 mRNA，IL-17E mRNA and MDSC percentage in rectal cancer group were higher than those in healthy control group（P<0.05），and the relative expression level of RORα mRNA was lower than that in healthy control group（P<0.05）. The relative expression levels of FOXP3 mRNA，IL-17E mRNA and MDSC percentage in rectal cancer patients with lymph metastasis and TNM stage Ⅲ were higher than those in patients without lymph metastasis and TNM stage Ⅰ-Ⅱ（P<0.05），and the relative expression level of RORα mRNA was lower than that in patients without lymph metastasis and TNM stage Ⅰ-Ⅱ（P<0.05）. There was no statistical significance in RORα mRNA，FOXP3 mRNA，IL-17E mRNA relative expression levels and MDSC percentage in rectal cancer patients with different sex，ages and tumor diameters（P>0.05）. Conclusions IL-17E mRNA and FOXP3 mRNA expressions and MDSC percentage are increased，and RORα mRNA expression is decreased in patients with rectal cancer. These indicators are related to TNM stage and lymph metastasis，and they may be used as screening and disease monitoring indicators for rectal cancer.

Key words: Retinoid-related orphan receptor alpha, Interleukin-17E, Forkhead box protein P3, Myeloid-derived suppressor cell, Peripheral blood mononuclear cell, Rectal cancer

CLC Number:

R446.1

YANG Yanmin, PENG MengLe, LIAN Wenping. MDSC percentage and the expressions of RORα mRNA，IL-17E mRNA and FOXP3 mRNA in rectal cancer patients[J]. Laboratory Medicine, 2023, 38(1): 23-27.

Figures/Tables 2

References 17

[1]	赵峰. 血浆SEPT9基因甲基化在Ⅰ-Ⅲ期结直肠癌手术疗效评估和术后复发监测的价值研究[D]. 乌鲁木齐: 新疆医科大学, 2021.
[2]	PAN H D, ZHAO G, AN Q, et al. Pulmonary metastasis in rectal cancer:a retrospective study of clinicopathological characteristics of 404 patients in Chinese cohort[J]. BMJ Open, 2018, 8(2):e019614. DOI URL
[3]	LLUIS A, BALLENBERGER N, ILLI S, et al. Regulation of TH17 markers early in life through maternal farm exposure[J]. J Allergy Clin Immunol, 2014, 133(3):864-871. DOI PMID
[4]	WEI C, SIRIKANJANAPONG S, LIEBERMAN S, et al. Primary mucosal melanoma arising from the eustachian tube with CTLA-4,IL-17A,IL-17C,and IL-17E upregulation[J]. Ear Nose Throat J, 2013, 92(1):36-40. DOI URL
[5]	HOECHST B, GAMREKELASHVILI J, MANNS M P, et al. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells[J]. Blood, 2011, 117(24):6532-6541. DOI PMID
[6]	VERMA C, EREMIN J M, ROBINS A, et al. Abnormal T regulatory cells(Tregs:FOXP3+,CTLA-4+),myeloid-derived suppressor cells(MDSCs:monocytic,granulocytic) and polarised T helper cell profiles(Th1,Th2,Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy(NAC) and surgery:failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC[J]. J Transl Med, 2013, 11:16. DOI
[7]	Diagnosis and Treatment Guidelines for Colorectal Cancer Working Group CSOCOC. Chinese Society of Clinical Oncology(CSCO) diagnosis and treatment guidelines for colorectal cancer 2018(English version)[J]. Chin J Cancer Res, 2019, 31(1):117-134. DOI URL
[8]	兰巧芬, 耿有全, 张诗颜, 等. 结直肠癌患者血清组织蛋白酶B与IL-22、IL-17水平的相关分析[J]. 检验医学与临床, 2021, 18(8):1051-1053.
[9]	曹亚萍, 赵国栋, 刘益, 等. 血浆胞裂蛋白9和多配体蛋白聚糖2前体甲基化联合检测与4种血清肿瘤标志物对结直肠癌诊断效果的对比性研究[J]. 中国综合临床, 2021, 37(2):105-111.
[10]	王小山, 祁义军, 俞浩远, 等. RORα与REV-ERBα在人胃癌组织表达情况及其临床意义[J]. 安徽医科大学学报, 2018, 53(3):411-415.
[11]	LIU A C, TRAN H G, ZHANG E E, et al. Redundant function of REV-ERBalpha and beta and non-essential role for Bmal1 cycling in transcriptional regulation of intracellular circadian rhythms[J]. PLoS Genet, 2008, 4(2):e1000023. DOI URL
[12]	WEI L, LIU M, XIONG H, et al. Up-regulation of IL-23 expression in human dental pulp fibroblasts by IL-17 via activation of the NF-κB and MAPK pathways[J]. Int Endod J, 2018, 51(6):622-631. DOI PMID
[13]	杨学良, 孙雪梅, 赵晓晖, 等. IL-17E和IL-17F及其受体在结直肠癌组织中的表达及其意义[J]. 吉林大学学报(医学版), 2018, 44(3):574-578.
[14]	TORGERSON T R, OCHS H D. Immune dysregulation,polyendocrinopathy,enteropathy,X-linked:forkhead box protein 3 mutations and lack of regulatory T cells[J]. J Allergy Clin Immunol, 2007, 120(4):744-750. DOI URL
[15]	杨蔺, 宗明, 卢添宝, 等. FOXP3和GITR/GITRL mRNA在类风湿关节炎和结直肠癌患者外周血中的表达研究[J]. 现代免疫学, 2008, 28(1):66-70.
[16]	黄茂, 陈露, 彭棋, 等. 结直肠癌患者外周血MDSCs与S100A9水平及其临床意义探讨[J]. 重庆医科大学学报, 2019, 44(11):1463-1468.
[17]	CROOK K R, JIN M, WEEKS M F, et al. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease[J]. J Leukoc Biol, 2015, 97(3):573-582. DOI URL

组别	例数	RORα mRNA	FOXP3 mRNA	IL-17E mRNA	MDSC百分比/%
直肠癌组	95	0.56±0.15	1.76±0.51	1.63±0.46	2.63±0.76
正常对照组	45	1.13±0.27	1.03±0.32	0.93±0.26	1.53±0.46
t值		16.038	8.807	9.503	8.953
P值		0.000	0.000	0.000	0.000

组别	例数	RORα mRNA	FOXP3 mRNA	IL-17E mRNA	MDSC百分比/%
直肠癌组	95	0.56±0.15	1.76±0.51	1.63±0.46	2.63±0.76
正常对照组	45	1.13±0.27	1.03±0.32	0.93±0.26	1.53±0.46
t值		16.038	8.807	9.503	8.953
P值		0.000	0.000	0.000	0.000

项目	例数	RORα mRNA	FOXP3 mRNA	IL-17E mRNA	MDSC百分比/%
性别
女	52	0.52±0.12	1.71±0.48	1.64±0.45	2.63±0.72
男	43	0.55±0.17	1.74±0.51	1.61±0.40	2.59±0.70
t值		1.006	0.295	0.340	0.273
P值		0.317	0.769	0.735	0.786
年龄
<50岁	35	0.55±0.14	1.73±0.50	1.60±0.39	2.58±0.67
≥50岁	60	0.58±0.16	1.70±0.49	1.63±0.42	2.65±0.74
t值		0.922	0.286	0.345	0.460
P值		0.359	0.776	0.731	0.646
肿瘤直径
<5 cm	55	0.56±0.14	1.68±0.47	1.58±0.36	2.53±0.62
≥5 cm	40	0.51±0.12	1.65±0.46	1.55±0.33	2.59±0.66
t值		1.823	0.310	0.415	0.453
P值		0.072	0.757	0.679	0.561
项目	例数	RORα mRNA	FOXP3 mRNA	IL-17E mRNA	MDSC百分比/%
淋巴转移
有	60	0.43±0.11	2.07±0.56	1.77±0.43	2.76±0.24
无	35	0.56±0.15	1.67±0.43	1.56±0.35	2.51±0.20
t值		4.876	3.778	2.537	5.369
P值		0.000	0.000	0.013	0.000
TNM 分期
Ⅰ~Ⅱ期	62	0.54±0.14	1.70±0.49	1.57±0.36	2.53±0.32
Ⅲ期	33	0.40±0.09	2.10±0.57	1.76±0.42	2.77±0.39
t值		4.980	3.577	2.310	3.222
P值		0.000	0.000	0.023	0.002

项目	例数	RORα mRNA	FOXP3 mRNA	IL-17E mRNA	MDSC百分比/%
性别
女	52	0.52±0.12	1.71±0.48	1.64±0.45	2.63±0.72
男	43	0.55±0.17	1.74±0.51	1.61±0.40	2.59±0.70
t值		1.006	0.295	0.340	0.273
P值		0.317	0.769	0.735	0.786
年龄
<50岁	35	0.55±0.14	1.73±0.50	1.60±0.39	2.58±0.67
≥50岁	60	0.58±0.16	1.70±0.49	1.63±0.42	2.65±0.74
t值		0.922	0.286	0.345	0.460
P值		0.359	0.776	0.731	0.646
肿瘤直径
<5 cm	55	0.56±0.14	1.68±0.47	1.58±0.36	2.53±0.62
≥5 cm	40	0.51±0.12	1.65±0.46	1.55±0.33	2.59±0.66
t值		1.823	0.310	0.415	0.453
P值		0.072	0.757	0.679	0.561
项目	例数	RORα mRNA	FOXP3 mRNA	IL-17E mRNA	MDSC百分比/%
淋巴转移
有	60	0.43±0.11	2.07±0.56	1.77±0.43	2.76±0.24
无	35	0.56±0.15	1.67±0.43	1.56±0.35	2.51±0.20
t值		4.876	3.778	2.537	5.369
P值		0.000	0.000	0.013	0.000
TNM 分期
Ⅰ~Ⅱ期	62	0.54±0.14	1.70±0.49	1.57±0.36	2.53±0.32
Ⅲ期	33	0.40±0.09	2.10±0.57	1.76±0.42	2.77±0.39
t值		4.980	3.577	2.310	3.222
P值		0.000	0.000	0.023	0.002